ETF universe handoff

Opening ETF evidence benchSynchronizing prices, risk metrics, holdings coverage, and source lineage

Company context

Shanghai Allist Pharmaceuticals Co. Ltd. Class A

SSE:688578

Pharmaceuticals: Major · benchmarked against KSTR constituent company universe inside the KSTR constituent company universe.

Active tabFinancial reports

Current readGood

Last close114.70

1M return+38.09%

Open symbol page Watchlist context

OverviewVerdict, thesis map, and valuation setup.FundamentalsDrivers, trajectory, and business quality.Financial reportsStatement tables, sorting, filtering, and acceleration.Ex-ante forecastTarget price, dividend yield, and total return by horizon.FactorsCompany factor exposure, rank, and universe context.Market viewMomentum, catalysts, charts, and symbol packet.AttributionLarge-move causes, residuals, and research backlog.OwnershipSEC 13F holder flow, crowding, and manager changes.PeersPeer heatmap and closest comparables.

Tab scope

Raw financial statements

Financial reports

Source and lookbackStored financial report rows1 report snapshots; latest report Jul 19, 2:40 PM GMT+8.

Sample and caveat24 reported metrics across 4 sections.Use this tab for its stated job; heavier model packets stay on their own tabs.

Traditional statement tables

Financial reports

1 reports · latest Jul 19, 2:40 PM GMT+8

Distinct report rows1

Sections4

Metrics shown24of 28 tracked

Coverage86%

CompanyShanghai Allist Pharmaceuticals Co. Ltd. Class A

Overview scoring

Fundamental overview

73/100 blended · 66/100 confidence · benchmark Closest peers

Blended fundamental score: Earnings 70/100; Cash flow 75/100; Balance sheet 72/100; Valuation 75/100.

Broad comparison

Cohort scorecard

Coverage-adjusted score with thinner cohorts automatically down-weighted

Cohort scorecard: Closest peers 73/100; Pharmaceuticals: Major 82/100; Health Technology 77/100; KSTR constituent company universe 71/100.

Selected company rank

Rank and percentile

Confidence-adjusted standing inside each cohort

Rank and percentile: Closest peers #1 of 13; Pharmaceuticals: Major #1 of 2; Health Technology #1 of 4; KSTR constituent company universe #1 of 49.

Section scoring matrix

Earnings, cash flow, balance sheet, and valuation

Heatmap score by cohort and statement section

Section scoring matrix: Closest peers Earnings 70/100; Cash flow 74/100; Balance sheet 72/100; Valuation 78/100.

Sort byFilter metrics

Specialist report review

Quant, PM, and risk-manager reads

Deterministic review lanes from stored report metrics

Quant review

Favorable acceleration0/1

At least three report snapshots are needed before the quant lane can rank acceleration.

Fundamental PM review

Growth and cash quality0/5

EPS TTM is 0.78 with Need 2 reports latest change. The PM lane checks revenue, EPS, cash flow, and margin confirmation together.

Risk manager review

Risk controls stableNo active flags

Debt / Equity is 0.00 with Need 2 reports latest change. The risk lane checks leverage, liquidity, and cash-yield deterioration.

Indexed report history

Financial report trend chart

First visible report = 100

Financial report trend chart: no chartable metrics.

Second order change

Acceleration chart

Favorable acceleration means the latest move improved versus the prior move

Acceleration chart: No non-zero acceleration yet.

PM / risk lens

Risk and quality radar

Directional score from change and acceleration

Risk and quality radar: Growth 50/100; Cash 50/100; Quality 50/100; Balance 50/100; Valuation 50/100.

Earnings

Metric trend table

8 of 10 metrics shown

Metric	Latest	Change	Acceleration	Trend	Samples
Total revenueRevenue	732.5M	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Revenue quarterRevenue	229.6M	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Operating income TTMEarnings	372.3M	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Operating marginProfitability	+50.83%	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
EPS TTMEarnings	0.78	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Gross marginQuality	+96.43%	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Net marginQuality	+42.57%	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1
Gross-to-net conversionQuality	+44.14%	Need 2 reportsNeed 2 reports	Need 3 reportsNeed 3 reports	stable	1

Historical statement rows

Earnings report history

1 dated rows

Snapshot date	Total revenue	Revenue quarter	Operating income TTM	Operating margin	EPS TTM	Gross margin	Net margin	Gross-to-net conversion
Jul 19, 2026	732.5M	229.6M	372.3M	+50.83%	0.78	+96.43%	+42.57%	+44.14%